CardiALLO cell therapy - BioCardia

Drug Profile

CardiALLO cell therapy - BioCardia

Alternative Names: CardiALLO

Latest Information Update: 23 Oct 2015

Price : $50

At a glance

  • Originator BioCardia
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Heart failure
  • Preclinical Myocardial infarction

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top